Induced pluripotent stem cells: New advances in cardiac regenerative medicine

Shinsuke Yuasa, Mitsushige Murata, Keiichi Fukuda

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

To bring the notion of cardiac regenerative medicine to fruition, researchers have tried to determine which stem cells, embryonic stem (ES) cells or somatic stem cells, are most suitable. Thus far, there is no clear indication which is better, because both have their own advantages and disadvantages. In 2006, murine induced pluripotent stem (iPS) cells were first established. Since then, basic research into the properties of iPS cells has continued apace. Originally, human iPS cells were generated from dermal fibroblasts by retrovirus-mediated gene transfer. Although this technique is sophisticated and easy to perform, the skin biopsy is accompanied by some bleeding and pain, and there may be some damage to the host genome because of retrovirus-mediated transgene integration. However, methods of producing iPS cells have improved steadily. For clinical application in the cardiovascular field, efficient methods that produce pluripotent stem cells that can differentiate into cardiomyocytes need to be developed. Existing methods for ES cells can be applied to iPS cells to obtain cardiomyocyte differentiation. In addition, existing purification methods can be used to obtain pure cardiomyocytes from a population of mixed cells. These techniques have themselves been the subject of extensive research, and continued advances are now making the clinical application of pluripotent stem cells a reality. We are at the forefront of medical innovations in the cardiovascular field based on the use of pluripotent stem cells.

Original languageEnglish
Title of host publicationEmerging Trends in Cell and Gene Therapy
PublisherHumana Press Inc.
Pages225-249
Number of pages25
ISBN (Print)9781627034173, 1627034161, 9781627034166
DOIs
Publication statusPublished - 2013 Dec 1

Fingerprint

Induced Pluripotent Stem Cells
Regenerative Medicine
Stem cells
Pluripotent Stem Cells
Cardiac Myocytes
Retroviridae
Embryonic Stem Cells
Skin
Adult Stem Cells
Transgenes
Research
Stem Cells
Fibroblasts
Research Personnel
Genome
Hemorrhage
Biopsy
Pain
Gene transfer
Population

Keywords

  • Cardiomyocyte
  • Differentiation
  • ES cells
  • iPS cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Yuasa, S., Murata, M., & Fukuda, K. (2013). Induced pluripotent stem cells: New advances in cardiac regenerative medicine. In Emerging Trends in Cell and Gene Therapy (pp. 225-249). Humana Press Inc.. https://doi.org/10.1007/978-1-62703-417-3_10

Induced pluripotent stem cells : New advances in cardiac regenerative medicine. / Yuasa, Shinsuke; Murata, Mitsushige; Fukuda, Keiichi.

Emerging Trends in Cell and Gene Therapy. Humana Press Inc., 2013. p. 225-249.

Research output: Chapter in Book/Report/Conference proceedingChapter

Yuasa, S, Murata, M & Fukuda, K 2013, Induced pluripotent stem cells: New advances in cardiac regenerative medicine. in Emerging Trends in Cell and Gene Therapy. Humana Press Inc., pp. 225-249. https://doi.org/10.1007/978-1-62703-417-3_10
Yuasa S, Murata M, Fukuda K. Induced pluripotent stem cells: New advances in cardiac regenerative medicine. In Emerging Trends in Cell and Gene Therapy. Humana Press Inc. 2013. p. 225-249 https://doi.org/10.1007/978-1-62703-417-3_10
Yuasa, Shinsuke ; Murata, Mitsushige ; Fukuda, Keiichi. / Induced pluripotent stem cells : New advances in cardiac regenerative medicine. Emerging Trends in Cell and Gene Therapy. Humana Press Inc., 2013. pp. 225-249
@inbook{163310eb3eae472fa2312a42e903ec6b,
title = "Induced pluripotent stem cells: New advances in cardiac regenerative medicine",
abstract = "To bring the notion of cardiac regenerative medicine to fruition, researchers have tried to determine which stem cells, embryonic stem (ES) cells or somatic stem cells, are most suitable. Thus far, there is no clear indication which is better, because both have their own advantages and disadvantages. In 2006, murine induced pluripotent stem (iPS) cells were first established. Since then, basic research into the properties of iPS cells has continued apace. Originally, human iPS cells were generated from dermal fibroblasts by retrovirus-mediated gene transfer. Although this technique is sophisticated and easy to perform, the skin biopsy is accompanied by some bleeding and pain, and there may be some damage to the host genome because of retrovirus-mediated transgene integration. However, methods of producing iPS cells have improved steadily. For clinical application in the cardiovascular field, efficient methods that produce pluripotent stem cells that can differentiate into cardiomyocytes need to be developed. Existing methods for ES cells can be applied to iPS cells to obtain cardiomyocyte differentiation. In addition, existing purification methods can be used to obtain pure cardiomyocytes from a population of mixed cells. These techniques have themselves been the subject of extensive research, and continued advances are now making the clinical application of pluripotent stem cells a reality. We are at the forefront of medical innovations in the cardiovascular field based on the use of pluripotent stem cells.",
keywords = "Cardiomyocyte, Differentiation, ES cells, iPS cells",
author = "Shinsuke Yuasa and Mitsushige Murata and Keiichi Fukuda",
year = "2013",
month = "12",
day = "1",
doi = "10.1007/978-1-62703-417-3_10",
language = "English",
isbn = "9781627034173",
pages = "225--249",
booktitle = "Emerging Trends in Cell and Gene Therapy",
publisher = "Humana Press Inc.",

}

TY - CHAP

T1 - Induced pluripotent stem cells

T2 - New advances in cardiac regenerative medicine

AU - Yuasa, Shinsuke

AU - Murata, Mitsushige

AU - Fukuda, Keiichi

PY - 2013/12/1

Y1 - 2013/12/1

N2 - To bring the notion of cardiac regenerative medicine to fruition, researchers have tried to determine which stem cells, embryonic stem (ES) cells or somatic stem cells, are most suitable. Thus far, there is no clear indication which is better, because both have their own advantages and disadvantages. In 2006, murine induced pluripotent stem (iPS) cells were first established. Since then, basic research into the properties of iPS cells has continued apace. Originally, human iPS cells were generated from dermal fibroblasts by retrovirus-mediated gene transfer. Although this technique is sophisticated and easy to perform, the skin biopsy is accompanied by some bleeding and pain, and there may be some damage to the host genome because of retrovirus-mediated transgene integration. However, methods of producing iPS cells have improved steadily. For clinical application in the cardiovascular field, efficient methods that produce pluripotent stem cells that can differentiate into cardiomyocytes need to be developed. Existing methods for ES cells can be applied to iPS cells to obtain cardiomyocyte differentiation. In addition, existing purification methods can be used to obtain pure cardiomyocytes from a population of mixed cells. These techniques have themselves been the subject of extensive research, and continued advances are now making the clinical application of pluripotent stem cells a reality. We are at the forefront of medical innovations in the cardiovascular field based on the use of pluripotent stem cells.

AB - To bring the notion of cardiac regenerative medicine to fruition, researchers have tried to determine which stem cells, embryonic stem (ES) cells or somatic stem cells, are most suitable. Thus far, there is no clear indication which is better, because both have their own advantages and disadvantages. In 2006, murine induced pluripotent stem (iPS) cells were first established. Since then, basic research into the properties of iPS cells has continued apace. Originally, human iPS cells were generated from dermal fibroblasts by retrovirus-mediated gene transfer. Although this technique is sophisticated and easy to perform, the skin biopsy is accompanied by some bleeding and pain, and there may be some damage to the host genome because of retrovirus-mediated transgene integration. However, methods of producing iPS cells have improved steadily. For clinical application in the cardiovascular field, efficient methods that produce pluripotent stem cells that can differentiate into cardiomyocytes need to be developed. Existing methods for ES cells can be applied to iPS cells to obtain cardiomyocyte differentiation. In addition, existing purification methods can be used to obtain pure cardiomyocytes from a population of mixed cells. These techniques have themselves been the subject of extensive research, and continued advances are now making the clinical application of pluripotent stem cells a reality. We are at the forefront of medical innovations in the cardiovascular field based on the use of pluripotent stem cells.

KW - Cardiomyocyte

KW - Differentiation

KW - ES cells

KW - iPS cells

UR - http://www.scopus.com/inward/record.url?scp=84929916877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929916877&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-417-3_10

DO - 10.1007/978-1-62703-417-3_10

M3 - Chapter

AN - SCOPUS:84929916877

SN - 9781627034173

SN - 1627034161

SN - 9781627034166

SP - 225

EP - 249

BT - Emerging Trends in Cell and Gene Therapy

PB - Humana Press Inc.

ER -